Циклическая терапия симптоматической дивертикулярной болезни рифаксимином и растворимыми пищевыми волокнами – эффективная профилактика осложнений
https://doi.org/10.21518/2079-701X-2019-3-98-107
Аннотация
В статье рассматриваются актуальные проблемы ведения больных с дивертикулярной болезнью толстой кишки. Распространенность патологии неуклонно растет, что обусловлено более частой диагностикой заболевания и увеличением продолжительности жизни населения. Между тем неправильные подходы к ведению данной категории больных могут оборачиваться развитием грозных осложнений, часто приводящих к фатальному исходу. В работе представлены данные об эффективности лечения дивертикулярной болезни толстой кишки рифаксимином, в т. ч. с применением циклических курсов, достоверно снижающих риск развития осложнений. Особое внимание уделено роли пищевых волокон для профилактики развития воспаления при дивертикулярной болезни, в т. ч. в сочетании с рифаксимином.
Об авторе
Е. В. Голованова
Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской Федерации
Россия
Россия
д.м.н., профессор кафедры поликлинической терапии,
127473, г. Москва, ул. Делегатская, д. 20, стр. 1
Список литературы
1. Cuomo R., Barbara G., Annibale B. Rifaximin and Diverticular disease: Position Paper of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease/.http://dx.doi.org/10.1016/j.dld.2017.01.164
2. Маев И.В., Дичева Д.Т., Андреев Д.Н., Лебедева Е.Г., Баева Т.А. Дивертикулярная болезнь толстой кишки. М., 2015. 22 с.
3. Валенкевич Л.Н., Яхонтов О.И. Болезни органов пищеварения. Руководство по гастроэнтерологии для врачей. СПб.: Изд-во ДЕАН, 2006. 656 с.
4. Логинов А.С., Парфенов А.И. Болезни кишечника. М., 2000:507–512.
5. Основы колопроктологии. Под ред. Г.И. Воробьева. М.: Мед.информ. агенство, 2006. 432 с.
6. Шептулин А.А. Дивертикулярная болезнь толстой кишки: клинические формы, диагностика, лечение. Рос. журн. гастроэнтерол. гепатол., колопроктол. 2006;5:44–49.
7. Parra-Blanco A. Colonic diverticular disease: Pathophysiology and clinical picture. Digestion. 2006;73(Suppl 1):47–57.
8. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-11.
9. Jeyarajah S., Faiz O., Bottle A., et al. Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions. Aliment Pharmal Ther. 2009;30:1171-82.
10. Tursi A., Papa A. & Danese S. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Aliment Pharmacol Ther. 2015;42:664–684.
11. Strate L.L., Modi R., Cohen E., et al. Diverticular disease as a chronic illness evolving epidemiologic and clinical insights. Am J Gastroenterol. 2012;107:1486–1493.
12. Shahedi K., Fuller G., Bolus R., et al. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol. 2013;12:1609-13
13. Комаров Ф.И., Осадчук М.А., Осадчук А.М. Практическая гастроэнтерология. М.: Медицинское информационное агентство, 2010. 480 с.
14. Практическое руководство Всемирной организации гастроэнтерологов (ВОГ-OMGE). Дивертикулярная болезнь. 2007.42 с.
15. Семионкин Е.И. Колопроктология. М.: Медпрактика, 2004.
16. Stollman N., Raskin J.B. Diverticular disease of the colon. Lancet. 2004;363:631-39.
17. Klarenbeek B.R., De Korte N., Van der Peet D.L. et al. Review of current classifications for diverticular disease and a translation into clinical practice. Int. J Colorectal Dis. 2012;27:207-14.
18. Jung H.K., Choung R.S., Locke G.R. 3rd, et al. Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol. 2010;105:652- 61.
19. Salemi T.A., Molloy R.G., O’Dwyer P.J. Prospective, five-year follow-up study of patients with symptomatic uncomplicated diverticular disease. Dis Colon Rectum. 2007;50:1460-64.
20. Floch M.H. Symptom severity and disease acitivity indices for diverticulitis. J Clin Gastroenterol. 2008;42:1135-36.
21. Pfutzer R.H., Kruis W. Management of diverticular disease. Nat Rev Gastroenterol Hepatol. 2015 Nov;12(11):629-38.
22. Ивашкин В.Т., Шелыгин Ю.А., Ачкасов С.И. и др. Рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению взрослых больных дивертикулярной болезнью ободочной кишки. РЖГГК. 2016;1:65-80.
23. Резолюция Всероссийского съезда колопроктологов http://akr-congress2016.ru/upload/files/astrakhan-2016-resolution.pdf. (In Russ).
24. Ridgway P.F., Latif A., Shabbir J. et al. Rando mized controlled trial of oral vs intravenous therapy for the clinically diagnosed acute uncomplicated diverticulitis. Colorectal Dis. 2008;11:941-6.
25. Chabok A., Pahlman L., Hjern F. et al. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg. 2012;30. doi:10.1002/bjs.8688.
26. Hjern F., Josephson T., Altman D. et al. Conservative treatment of acute diverticulitis: are antibiotics always mandatory? Scand J Gastroenterol. 2007;42(1):41-7.
27. Tursi A., Papa A. & Danese S. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Aliment Pharmacol Ther. 2015;42:664–684.
28. Cuomo R., Barbara G., Pace F., Annese V., Bassotti G., Binda G.A., Casetti T., Colecchia A., Festi D., Fiocca R., Laghi A., Maconi G., Nascimbeni R., Scarpignato C., Villanacci V. and Annibale B. Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal. 2014;2(5):413–442.
29. Trespi E., Colla C., Panizza P., Polino M.G., Venturini A., Bottani G., et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the colon: 4-year follow-up results. Minerva Gastroenterol Dietol. 1999;45:245-52.
30. Jiang Z.D., Ke S., Palazzini E., Riopel L., Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205-2206. PMID: 10898704.
31. Marzo et al. Dig. Liv. Dis. 2010;42S:S61-s192. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.
32. Ponziani F.R., Zocco M.A., D’Aversa F., Pompili M., Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23(25):4491-4499. Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i25/4491.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i25.4491.
33. Brigidi P., Swennen E., Rizzello F., Bozzolasco M., Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002;14:290-295. PMID: 12120885. doi: 10.1179/joc.2002.14.3.290.
34. Maccaferri S., Vitali B., Klinder A., Kolida S., Ndagijimana M., Laghi L., Calanni F., Brigidi P., Gibson G.R., Costabile A. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65:2556-2565. doi: 10.1093/jac/dkq345. PMID: 20852272.
35. Xu D., Gao J. Gillilland M. 3rd, Wu X., Song I., Kao J.Y., Owyang C. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146:484-496.e4. PMID: 24161699. doi: 10. 1053/j.gastro.2013.10.026.
36. Soldi S., Vasileiadis S., Uggeri F., Campanale M., Morelli L., Fogli M.V., Calanni F., Grimaldi M., Gasbarrini A. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309- 325. doi: 10. 2147/CEG.S89999. PMID: 26673000.
37. Ponziani F.R., Scaldaferri F., Petito V., Paroni Sterbini F., Pecere S., Lopetuso LR, Palladini A, Gerardi V, Masucci L, Pompili M, Cammarota G, Sanguinetti M, Gasbarrini A. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Dig Dis. 2016;34:269-278. doi: 10.1159/000443361. PMID: 27027301.
38. Ma X., Shah Y.M., Guo G.L., et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007;322:391-8.
39. Esposito G., Nobile N., Gigli S., et al. Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway. Front Pharmacol. 2016;9:120.
40. Terc J., Hansen A., Alston L., et al. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci. 2014;55:121-9.
41. Bianchi M., et al. Meta-analysis: longterm therapy with rifaximinin the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011;33:902-910.
42. Cuomo R., Barbara G., Pace F., Annese V., Bassotti G., Binda G.A., Casetti T., Colecchia A., Festi D., Fiocca R., Laghi A., Maconi G., Nascimbeni R., Scarpignato C., Villanacci V. and Annibale B. Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterology Journal. 2014;2(5):413–442.
43. Mullen K.D. et al. Rifaximin is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt hepatic Encephalopathy. Clinical Gastroenterology and Hepatology. 2014;12.
44. Colecchia A. et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterology. 2007 Janyary 14;13(2):264-269.
45. Adamberg K., Kolk K., Jaagura M., Vilu R. and Adamberg S. The composition and metabolism of faecal microbiota is specifically modulated by different dietary polysaccharides and mucin: an isothermal microcalorimetry study. 2017 Wageningen Academic Publishers. Doi: 10.3920/BM2016.0198.
46. Lanas A. et al. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: A proof-of-concept study. Digestive and Liver Disease. 2013;45(2):104-109.
47. Binder H.J., Mehta P. Short-chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. Gastroenterology. 1989;96:989–996.
48. Sakata T. Effects of sort chain fatty acids on epithelial cell proliferation and mucus release in the intestine. Proc. 10th Ross conf. on medical research «Short-chain fatty acids, metabolism and clinical importance». Miami, Florida, USA. 1991:63–67.
49. Kruh J., Tichonicky L., Defer N. Effect of butyrate on gene expression. In: Short chain fatty acids. Ed. H.J. Binder, J.H. Cummings. Kluwer Academic Publishers, Dordrecht (NL). 1994:135–147.
50. Robinson R.R., Causey J., Slavin J.L. Nutritional benefits of larch arabinogalactan // Advanced Dietary Fiber Technology. Ed. McCleary B.V., Prosky L. Blackwell Science Ltd.: Oxford, UK. 2001:443–451.
51. Mayeur S., Spahis Sch., Pouliot Y., and Levy E. Lactoferrin, a Pleiotropic Protein in Health and Disease. Antioxidants & Redox. Signaling. 2016;24(14):813–836. doi: 10.1089/ars.2015.6458.
52. Actor J.K., Hwang S.-A., Kruzel M.L. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15:1956–1973.
53. Artym J., Zimecki M., Paprocka M., Kruzel M.L. Orally administered lactoferrin restores humoral immune response in immunocompromised mice. Immunol Lett. 2003;89:9–15.
54. Kanyshkova T.G., Buneva V.N., and Nevinsky G.A. Lactoferrin and its biological functions. Biochemistry. 2001;66:1–7.
55. Blake D.R., Gallagher P.J., Potter A.R., Bell M.J., and Bacon P.A. The effect of synovial iron on the progression of rheumatoid disease. A histologic assessment of patients with early rheumatoid synovitis. Arthritis Rheum. 1984;27:495–501.
56. Latorre D., Berlutti F., Valenti P., Gessani S., and Puddu P. LF immunomodulatory strategies: mastering bacterial endotoxin. Biochem Cell Biol. 2012;90:269–278.
57. Baveye S., Elass E., Fernig D.G., Blanquart C., Mazurier J., and Legrand D. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14- lipopolysaccharide complex. Infect Immun. 2000;68:6519–6525.
58. Majka G.et al. The impact of lactoferrin with different levels of metal saturation on the intestinal epithelial barrier function and mucosal inflammation. Biometals. 2016;29:1019–1033.
59. Adlerova L. et al., Lactoferrin: a review. Veterinarni Medicina. 2008;53(9):457–468.
60. Hirotani Y. et al. Protective Effects of Lactoferrin against Intestinal Mucosal Damage Induced by Lipopolysaccharide in Human Intestinal Caco-2 Cells. Yakugaku Zasshi. 2008;128(9):1363-1368.
61. Hu W., Zhao J., Wang J., Yu T., Wang J., and Li N. Transgenic milk containing recombinant human lactoferrin modulates the intestinal flora in piglets. Biochem Cell Biol. 2012;90:485–496.
62. Mastromarino P., Capobianco D., Campagna G., Laforgia N., Drimaco P., Dileone A., and Baldassarre M.E. Correlation between lactoferrin and beneficial microbiota in breast milk and infant’s feces. Biometals. 2014;27:1077–1086.
63. Oda H., Wakabayashi H., Yamauchi K., and Abe F. Lactoferrin and bifidobacteria. Biometals. 2014;27:915–922.
64. Suzuki N., Murakoshi M., Ono T., Morishita S., Koide M., Bae M.J., Totsuka M., Shimizu M., Sugiyama K., Nishino H., and Iida N. Effects of Enteric-coated Lactoferrin Tablets Containing Lactobacillus brevis subsp. Coagulans on Fecal Properties, Defecation Frequency and Intestinal Microbiota of Japanese Women with a Tendency for Constipation: a Randomized Placebo-controlled Crossover Study. Biosci Microbiota Food Health. 2013;32:13–21.
65. Ochoa T.J., Pezo A., Cruz K., Chea-Woo E., and Cleary T.G. Clinical studies of lactoferrin in children. Biochem Cell Biol. 2012;90:457–467.
Рецензия
Для цитирования:
Голованова Е.В. Циклическая терапия симптоматической дивертикулярной болезни рифаксимином и растворимыми пищевыми волокнами – эффективная профилактика осложнений. Медицинский Совет. 2019;(3):98-107. https://doi.org/10.21518/2079-701X-2019-3-98-107
For citation:
Golovanova E.V. Cyclic rifaximin and soluble dietary fiber therapy for symptomatic diverticular disease: effective prevention of complications. Meditsinskiy sovet = Medical Council. 2019;(3):98-107. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-98-107
Просмотров: 789
Послать статью по эл. почте 